Literature DB >> 22800894

Different sensitivities to rocuronium of the neuromuscular junctions innervated by normal/damaged facial nerves and somatic nerve in rats: the role of the presynaptic acetylcholine quantal release.

Jun-Liang Chen1, Shao-Qin Li, Fang-Lu Chi, Lian-Hua Chen, Shi-Tong Li.   

Abstract

BACKGROUND: Muscles present different responses to muscle relaxants, a mechanism of importance in surgeries requiring facial nerve evoked electromyography under general anaesthesia. The non-depolarizing muscle relaxants have multiple reaction formats in the neuromuscular junction, in which pre-synaptic quantal release of acetylcholine was one of the important mechanisms. This study was to compare the pre-synaptic quantal release of acetylcholine from the neuromuscular junctions innervated by normal/damaged facial nerves and somatic nerve under the effect of rocuronium in rats in vitro.
METHODS: Acute right-sided facial nerve injury was induced by nerve crush axotomies. Both sided facial nerve connected orbicularis oris strips and tibial nerve connected gastrocnemius strips were isolated to measure endplate potentials (EPP) and miniature endplate potentials (MEPP) using an intracellular microelectrode gauge under different rocuronium concentrations. Then, the pre-synaptic quantal releases of acetylcholine were calculated by the ratios of the EPPs and the MEPPs, and compared among the damaged or normal facial nerve innervated orbicularis oris and tibial nerve innervated gastrocnemius.
RESULTS: The EPP/MEPP ratios of the three neuromuscular junctions decreased in a dose dependent manner with the increase of the rocuronium concentration. With the concentrations of rocuronium being 5 µg/ml, 7.5 µg/ml and 10 µg/ml, the decrease of the EPP/MEPP ratio in the damaged facial nerve group was greater than that in the normal facial nerve group. The decrease in the somatic nerve group was the biggest, with significant differences.
CONCLUSIONS: Rocuronium presented different levels of inhibition on the pre-synaptic quantal release of acetylcholine in the three groups of neuromuscular junctions. The levels of the inhibition showed the following sequence: somatic nerve > damaged facial nerve > normal facial nerve. The difference may be one of the reasons causing the different sensitivities to rocuronium among the muscles innervated by the normal/injured facial nerves and the somatic nerve. The results may provide some information for the proper usage of muscle relaxants in surgeries requiring electromyographic monitoring for the pre-surgically impaired facial nerves.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22800894

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  4 in total

1.  Effect of rocuronium on the level and mode of pre-synaptic acetylcholine release by facial and somatic nerves, and changes following facial nerve injury in rabbits.

Authors:  Jinghua Tan; Jing Xu; Yian Xing; Lianhua Chen; Shitong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Differences in pharmacodynamic responses to rocuronium in normal or injured orbicularis oris are associated with expression of acetylcholine receptor subunits.

Authors:  Yong Huang; Yian Xing; Hong Wang; Lianhua Chen; Shitong Li
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

3.  Inhibiting Matrix Metalloproteinases Protects Evoked Electromyography Amplitudes and Muscle Tension in the Orbicularis Oris Muscle in a Rat Model of Facial Nerve Injury.

Authors:  Shuang Wu; Lijun Song; Meirong Yu; Chao Gong; Lianhua Chen
Journal:  J Neuropathol Exp Neurol       Date:  2022-09-19       Impact factor: 3.148

4.  Overexpression of Foxc1 regenerates crushed rat facial nerves by promoting Schwann cells migration via the Wnt/β-catenin signaling pathway.

Authors:  Wenzheng Xia; Jin Zhu; Xueyi Wang; Yinda Tang; Ping Zhou; Xiangyu Wei; Bowen Chang; Xuan Zheng; Wanchun Zhu; Meng Hou; Shiting Li
Journal:  J Cell Physiol       Date:  2020-05-11       Impact factor: 6.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.